Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

New mutation L324M in the ABL1 kinase domain: does it confer high resistance to second-generation inhibitors?

Leukemia & lymphoma - 1 Mar 2014

Noriega María Fernanda, Ferri Cristian Alberto, Icardi Gustavo, Bullorsky Eduardo, Korin Jorge, Larripa Irene

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Amino Acid Substitution
Share to Codon
Share to Drug Resistance, Neoplasm
Share to Fusion Proteins, bcr-abl

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Share to Mutation

Share to Protein Interaction Domains and Motifs

Share to Protein Kinase Inhibitors

Source

Identifiers

PMID: 23741973
DOI: 10.3109/10428194.2013.810735

Genes

ABL1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

New mutation L324M in the ABL1 kinase domain: does it confer high resistance to second-generation inhibitors?PMID 23741973Read ↗

Another tyrosine kinase inhibitor-resistance mutation within the BCR-ABL kinase domain: chasing our tails?Semantic proximity Read ↗

T315L: a novel mutation within BCR-ABL kinase domain confers resistance against ponatinib.Semantic proximity Read ↗

F317L BCR-ABL1 kinase domain mutation associated with a sustained major molecular response in a CML patient on dasatinib.Semantic proximity Read ↗

BCR-ABL kinase domain mutations, including 2 novel mutations in imatinib resistant Malaysian chronic myeloid leukemia patients—Frequency and clinical outcomeSemantic proximity Read ↗

Identification of novel BCR::ABL1 kinase domain mutation in patients with chronic myeloid leukaemia and imatinib resistance.Semantic proximity Read ↗

Implications of BCR-ABL1 kinase domain-mediated resistance in chronic myeloid leukemia.Semantic proximity Read ↗

Effect of low-level BCR-ABL1 kinase domain mutations identified by next-generation sequencing in patients with chronic myeloid leukaemia: a population-based studySemantic proximity Read ↗

Three novel patient-derived BCR/ABL mutants show different sensitivity to second and third generation tyrosine kinase inhibitors.Semantic proximity Read ↗

Novel ABL1 mutation in a Moroccan CML patient with Imatinib resistance.Semantic proximity Read ↗

Resistance mutations in CML and how we approach them.Semantic proximity Read ↗

BCR-ABL1 compound mutations drive ponatinib resistance.Semantic proximity Read ↗

Characteristics of BCR-ABL kinase domain mutations in chronic myeloid leukemia from India: not just missense mutations but insertions and deletions are also associated with TKI resistance.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.